Synthesis and evaluation of antimalarial properties of novel 4-aminoquinoline hybrid compounds

Chemical Biology and Drug Design

Volumn 84, Issue 4, 2014, Pages 462-472

  Fisher, Gillian M ^a   Tanpure, Rajendra P ^a   Douchez, Antoine ^a   Andrews, Katherine T ^a   Poulsen, Sally Ann ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

antimalarial; carbonic anhydrase; chloroquine; click chemistry; hybrid; Plasmodium falciparum; primary sulfonamide; sulfonamide

Indexed keywords

4-AMINOQUINOLINE; AMINOQUINOLINE DERIVATIVE; ANTIMALARIAL AGENT; SULFONAMIDE;

CELL LINE; CELL SURVIVAL; CHEMISTRY; CLICK CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; PLASMODIUM FALCIPARUM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

AMINOQUINOLINES; ANTIMALARIALS; CELL LINE; CELL SURVIVAL; CLICK CHEMISTRY; DRUG DESIGN; DRUG RESISTANCE; HUMANS; PLASMODIUM FALCIPARUM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 84921363121     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12335     Document Type: Article

References (53)

1. Murray C.J., Rosenfeld L.C., Lim S.S., Andrews K.G., Foreman K.J., Haring D., Fullman N., Naghavi M., Lozano R., Lopez A.D., (2012) Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet; 379: 413-431.
2. Dondorp A.M., Nosten F., Yi P., Das D., Phyo A.P., Tarning J., Lwin K.M., et al,. (2009) Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med; 361: 455-467.
3. Dondorp A.M., Yeung S., White L., Nguon C., Day N.P.J., Socheat D., von Seidlein L., (2010) Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol; 8: 272-280.
4. Payne D., (1987) Spread of chloroquine resistance in Plasmodium falciparum. Parasitol Today; 3: 241-246.
5. Roper C., Pearce R., Bredenkamp B., Gumede J., Drakeley C., Mosha F., Chandramohan D., Sharp B., (2003) Antifolate antimalarial resistance in southeast Africa: a population-based analysis. Lancet; 361: 1174-1181.
6. Nair S., Williams J.T., Brockman A., Paiphun L., Mayxay M., Newton P.N., Guthmann J.P., Smithuis F.M., Hien T.T., White N.J., Nosten F., Anderson T.J., (2003) A selective sweep driven by pyrimethamine treatment in southeast asian malaria parasites. Mol Biol Evol; 20: 1526-1536.
7. Dondorp A.M., Ringwald P., (2013) Artemisinin resistance is a clear and present danger. Trends Parasitol; 29: 359-360.
8. Kouznetsov V.V., Gomez-Barrio A., (2009) Recent developments in the design and synthesis of hybrid molecules based on aminoquinoline ring and their antiplasmodial evaluation. Eur J Med Chem; 44: 3091-3113.
9. Egan T.J., (2001) Structure-function relationships in chloroquine and related 4-aminoquinoline antimalarials. Mini Rev Med Chem; 1: 113-123.
10. Benoit-Vical F., Lelievre J., Berry A., Deymier C., Dechy-Cabaret O., Cazelles J., Loup C., Robert A., Magnaval J.F., Meunier B., (2007) Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes. Antimicrob Agents Chemother; 51: 1463-1472.
11. Biot C., Nosten F., Fraisse L., Ter-Minassian D., Khalife J., Dive D., (2011) The antimalarial ferroquine: from bench to clinic. Parasite; 18: 207-214.
12. Daher W., Biot C., Fandeur T., Jouin H., Pelinski L., Viscogliosi E., Fraisse L., Pradines B., Brocard J., Khalife J., Dive D., (2006) Assessment of Plasmodium falciparum resistance to ferroquine (SSR97193) in field isolates and in W2 strain under pressure. Malar J; 5: 11.
13. Manohar S., Khan S.I., Rawat D.S., (2013) 4-aminoquinoline-triazine-based hybrids with improved in vitro antimalarial activity against CQ-sensitive and CQ-resistant strains of Plasmodium falciparum. Chem Biol Drug Des; 81: 625-630.
14. Raj R., Singh P., Gut J., Rosenthal P.J., Kumar V., (2013) Azide-alkyne cycloaddition en route to 1H-1,2,3-triazole-tethered 7-chloroquinoline-isatin chimeras: synthesis and antimalarial evaluation. Eur J Med Chem; 62: 590-596.
15. Ribeiro C.J., Kumar S.P., Gut J., Goncalves L.M., Rosenthal P.J., Moreira R., Santos M.M., (2013) Squaric acid/4-aminoquinoline conjugates: novel potent antiplasmodial agents. Eur J Med Chem; 69C: 365-372.
16. Singh P., Raj R., Singh P., Gut J., Rosenthal P.J., Kumar V., (2013) Urea/oxalamide tethered beta-lactam-7-chloroquinoline conjugates: synthesis and in vitro antimalarial evaluation. Eur J Med Chem; 71C: 128-134.
17. Meunier B., (2008) Hybrid molecules with a dual mode of action: dream or reality? Acc Chem Res; 41: 69-77.
18. O'Neill P.M., Bray P.G., Hawley S.R., Ward S.A., Park B.K., (1998) 4-Aminoquinolines-past, present, and future: a chemical perspective. Pharmacol Ther; 77: 29-58.
19. Foley M., Tilley L., (1998) Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents. Pharmacol Ther; 79: 55-87.
20. Yayon A., Cabantchik Z.I., Ginsburg H., (1984) Identification of the acidic compartment of Plasmodium falciparum-infected human erythrocytes as the target of the antimalarial drug chloroquine. EMBO J; 3: 2695-2700.
21. Ginsburg H., Ward S.A., Bray P.G., (1999) An integrated model of chloroquine action. Parasitol Today; 15: 357-360.
22. White N.J., Miller K.D., Churchill F.C., Berry C., Brown J., Williams S.B., Greenwood B.M., (1988) Chloroquine treatment of severe malaria in children. Pharmacokinetics, toxicity, and new dosage recommendations. N Engl J Med; 319: 1493-1500.
23. Manohar S., Khan S.I., Rawat D.S., (2011) Synthesis of 4-aminoquinoline-1,2,3-triazole and 4-aminoquinoline-1,2,3-triazole-1,3,5-triazine hybrids as potential antimalarial agents. Chem Biol Drug Des; 78: 124-136.
24. Melato S., Prosperi D., Coghi P., Basilico N., Monti D., (2008) A combinatorial approach to 2,4,6-trisubstituted triazines with potent antimalarial activity: combining conventional synthesis and microwave-assistance. ChemMedChem; 3: 873-876.
25. Manohar S., Khan S.I., Rawat D.S., (2010) Synthesis, antimalarial activity and cytotoxicity of 4-aminoquinoline-triazine conjugates. Bioorg Med Chem Lett; 20: 322-325.
26. Manohar S., Rajesh U.C., Khan S.I., Tekwani B.L., Rawat D.S., (2012) Novel 4-aminoquinoline-pyrimidine based hybrids with improved in vitro and in vivo antimalarial activity. ACS Med Chem Lett; 3: 555-559.
27. Cosledan F., Fraisse L., Pellet A., Guillou F., Mordmuller B., Kremsner P.G., Moreno A., Mazier D., Maffrand J.P., Meunier B., (2008) Selection of a trioxaquine as an antimalarial drug candidate. Proc Natl Acad Sci U S A; 105: 17579-17584.
28. Olliaro P., Wells T.N., (2009) The global portfolio of new antimalarial medicines under development. Clin Pharmacol Ther; 85: 584-595.
29. de Pilla Varotti.F., Botelho A.C., Andrade A.A., de Paula R.C., Fagundes E.M., Valverde A., Mayer L.M., Mendonca J.S., de Souza M.V., Boechat N., Krettli A.U., (2008) Synthesis, antimalarial activity, and intracellular targets of MEFAS, a new hybrid compound derived from mefloquine and artesunate. Antimicrob Agents Chemother; 52: 3868-3874.
30. Dive D., Biot C., (2008) Ferrocene conjugates of chloroquine and other antimalarials: the development of ferroquine, a new antimalarial. ChemMedChem; 3: 383-391.
31. Kelly J.X., Smilkstein M.J., Brun R., Wittlin S., Cooper R.A., Lane K.D., Janowsky A., Johnson R.A., Dodean R.A., Winter R., Hinrichs D.J., Riscoe M.K., (2009) Discovery of dual function acridones as a new antimalarial chemotype. Nature; 459: 270-273.
32. O'Neill P.M., Amewu R.K., Nixon G.L., Bousejra ElGarah F., Mungthin M., Chadwick J., Shone A.E., et al,. (2010) Identification of a 1,2,4,5-tetraoxane antimalarial drug-development candidate (RKA 182) with superior properties to the semisynthetic artemisinins. Angew Chem Int Ed Engl; 49: 5693-5697.
33. Andrews K.T., Fisher G.M., Sumanadasa S.D., Skinner-Adams T., Moeker J., Lopez M., Poulsen S.A., (2013) Antimalarial activity of compounds comprising a primary benzene sulfonamide fragment. Bioorg Med Chem Lett; 23: 6114-6117.
34. Supuran C.T., (2008b) Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov; 7: 168-181.
35. Bahn Y.S., Cox G.M., Perfect J.R., Heitman J., (2005) Carbonic anhydrase and CO2 sensing during Cryptococcus neoformans growth, differentiation, and virulence. Curr Biol; 15: 2013-2020.
36. Covarrubias A.S., Bergfors T., Jones T.A., Hogbom M., (2006) Structural mechanics of the pH-dependent activity of beta-carbonic anhydrase from Mycobacterium tuberculosis. J Biol Chem; 281: 4993-4999.
37. Klengel T., Liang W.J., Chaloupka J., Ruoff C., Schroppel K., Naglik J.R., Eckert S.E., Mogensen E.G., Haynes K., Tuite M.F., Levin L.R., Buck J., Muhlschlegel F.A., (2005) Fungal adenylyl cyclase integrates CO2 sensing with cAMP signaling and virulence. Curr Biol; 15: 2021-2026.
38. Nishimori I., Minakuchi T., Kohsaki T., Onishi S., Takeuchi H., Vullo D., Scozzafava A., Supuran C.T., (2007) Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors. Bioorg Med Chem Lett; 17: 3585-3594.
39. Nishimori I., Minakuchi T., Morimoto K., Sano S., Onishi S., Takeuchi H., Vullo D., Scozzafava A., Supuran C.T., (2006) Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs. J Med Chem; 49: 2117-2126.
40. Pan P., Vermelho A.B., Capaci Rodrigues G., Scozzafava A., Tolvanen M.E., Parkkila S., Capasso C., Supuran C.T., (2013) Cloning, characterization, and sulfonamide and thiol inhibition studies of an alpha-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease. J Med Chem; 56: 1761-1771.
41. Supuran C.T., (2011) Bacterial carbonic anhydrases as drug targets: toward novel antibiotics? Front Pharmacol; 2: 34.
42. Vollrath S.B., Furniss D., Schepers U., Brase S., (2013) Amphiphilic peptoid transporters-synthesis and evaluation. Org Biomol Chem; 11: 8197-8201.
43. Wilkinson B.L., Innocenti A., Vullo D., Supuran C.T., Poulsen S.A., (2008) Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides. J Med Chem; 51: 1945-1953.
44. Wischeler J.S., Sun D., Sandner N.U., Linne U., Heine A., Koert U., Klebe G., (2011) Stereo- and regioselective azide/alkyne cycloadditions in carbonic anhydrase II via tethering, monitored by crystallography and mass spectrometry. Chemistry; 17: 5842-5851.
45. Das J., Patil S.N., Awasthi R., Narasimhulu C.P., Trehan S., (2005) An easy access to aryl azides from aryl amines under neutral conditions. Synthesis; 11: 1801-1806.
46. Salmon A.J., Williams M.L., Wu Q.K., Morizzi J., Gregg D., Charman S.A., Vullo D., Supuran C.T., Poulsen S.A., (2012) Metallocene-based inhibitors of cancer-associated carbonic anhydrase enzymes IX and XII. J Med Chem; 55: 5506-5517.
47. Oduola A.M., Weatherly N.F., Bowdre J.H., Desjardins R.E., (1988) Plasmodium falciparum: cloning by single-erythrocyte micromanipulation and heterogeneity in vitro. Exp Parasitol; 66: 86-95.
48. Noedl H., Wongsrichanalai C., Wernsdorfer W.H., (2003) Malaria drug-sensitivity testing: new assays, new perspectives. Trends Parasitol; 19: 175-181.
49. Huber W., Koella J.C., (1993) A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites. Acta Trop; 55: 257-261.
50. Tron G.C., Pirali T., Billington R.A., Canonico P.L., Sorba G., Genazzani A.A., (2008) Click chemistry reactions in medicinal chemistry: applications of the 1,3-dipolar cycloaddition between azides and alkynes. Med Res Rev; 28: 278-308.
51. Malmquista N.A., Mossc T.A., Mecheria S., Scherfa A., Fuchter M.J., (2012) Small-molecule histone methyltransferase inhibitors display rapid antimalarial activity against all blood stage forms in Plasmodium falciparum. Proc Natl Acad Sci USA; 109: 16708-16713.
52. Novotny-Diermayr V., Sangthongpitag K., Hu C.Y., Wu X., Sausgruber N., Yeo P., Greicius G., (2010) SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther; 9: 642-652.
53. Sumanadasa S.D., Goodman C.D., Lucke A.J., Skinner-Adams T., Sahama I., Haque A., Do T.A., McFadden G.I., Fairlie D.P., Andrews K.T., (2012) Antimalarial activity of the anticancer histone deacetylase inhibitor SB939. Antimicrob Agents Chemother; 56: 3849-3856.